Healthy Volunteer Clinical Trial
Official title:
Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders
Verified date | June 20, 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Many people can learn to use feedback about brain activity to modify that activity, but
is it not known if people with Tourette syndrome can modify their brain activity.
- Researchers have evidence that certain areas of the brain are involved in causing tics
in people with Tourette syndrome. If people with Tourette syndrome can use feedback
about brain activity to modify activity in those parts of the brain, they may be able to
modify their brain activity to help control the tics.
Objectives:
- To determine if people with and without Tourette syndrome can learn to use thought to
control brain activity.
- To test whether people who have Tourette syndrome can learn to control brain activities,
possibly helping to control tics.
Eligibility:
- Healthy volunteers ages 18 and older who are right-handed and are willing to not consume
caffeine or alcohol for 24 hours before the study visit.
- Patients with Tourette syndrome who have tics that can be observed and studied.
- All participants must be able to undergo magnetic resonance imaging (MRI) scans.
Design:
- Healthy volunteers (two visits to the NIH Clinical Center over a 2- to 4-week period;
visit may last up to 3 hours):
- Screening visit, including physical examination and medical history, and a magnetic
resonance imaging (MRI) scan if the individual has not had one performed at the National
Institutes of Health in the past year.
- Study visit: Functional MRI (fMRI) scan to allow researchers to see if volunteers can
learn to control their brain activity during a scan. Volunteers will be asked to
complete tasks as directed during the fMRI scan.
- Patients with Tourette syndrome (three or four outpatient visits over a 4- to 6-week
period; each visit may last up to 4 hours):
- Screening visit, including physical examination and medical history, and an MRI scan if
the individual has not had one performed at the National Institutes of Health in the
past year.
- Evaluation visit to ask questions about Tourette symptoms and to have patients complete
questionnaires about their tics and their mental health.
- Study visit: fMRI scan to allow researchers to see if patients can learn to control
their brain activity during a scan. Patients will be asked to complete tasks as directed
during the fMRI scan.
- Final visit: Researchers will ask questions about tic symptoms, have patients complete
questionnaires, and perform a brief exam. Afterward, patients will have an fMRI scan
similar to the previous one.
- All participants will be paid a small amount of money in compensation for their
participation in the study.
Status | Terminated |
Enrollment | 59 |
Est. completion date | June 20, 2019 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
- INCLUSION CRITERIA: Healthy Volunteers 1. Aged 18 to 60 2. Right-hand dominant 3. Have a normal neurological exam 4. Have the capacity to give informed consent 5. Willing to abstain from caffeine and alcohol for 24 hours prior to MRI scanning TD Patients 1. Aged 18 to 60 2. Right-dominant 3. Have TS or chronic motor or vocal tic disorder diagnosis based on neurological examination and meeting criteria of the Diagnostic and Statistical Manual of Mental Disorders 4th 5th Edition (DSM-V) 4. Have the capacity to give informed consent 5. A Yale Global Tic Severity Scale (YGTSS) total score of at least 5 6. Willing to abstain from caffeine and alcohol for 24 hours prior to MRI scanning 7. If pharmacologically treated for TD, willing to not alter medication dosages or regimens between the screening visit and scanning visit for participants of Phase 2 or between the screening visit and follow-up visit for participants of Phase 3 EXCLUSION CRITERIA: Healthy Volunteers 1. Pregnancy 2. Any abnormal findings on neurological exam 3. Any finding on the MRI safety questionnaire that prevents them from safely undergoing an MRI scan 4. Any medical condition that would prevent them from lying flat for up to 3 hours 5. Any history of central nervous system infection or inflammation, brain tumor, stroke, head trauma or a vascular malformation as obtained by history or from imaging studies 6. Presence of any active or medically treated neurological conditions such as epilepsy, multiple sclerosis, or a movement disorder 7. Presence of any active or medically treated psychiatric problems such as depression, OCD or ADHD 8. Presence of uncontrolled medical illnesses such as heart, lung, or kidney disease 9. Presence of claustrophobia or other restriction that prevents them from undergoing a scan in a confined space for up to 3 hours 10. Presence of continuous or excessive movements at rest or are unable to remain supine while undergoing a scan for up to 3 hours. TD Patients 1. Pregnancy 2. Any finding on the MRI safety questionnaire that prevents them from safely undergoing an MRI scan 3. Any medical condition that would prevent them from lying flat for up to 3 hours 4. Any history of central nervous system infection or inflammation, brain tumor, stroke, head trauma or a vascular malformation as obtained by history or from imaging studies 5. Presence of uncontrolled psychiatric problems such as depression, OCD or ADHD 6. Patients with a history of a psychotic disorder such as schizophrenia 7. Patients with other movement disorders or progressive neurological disorders other than Tic disorders such as Multiple Sclerosis or epilepsy 8. Presence of uncontrolled medical illnesses such as heart, lung, or kidney disease 9. Presence of claustrophobia or other restrictions that prevent them from undergoing a scan in a confined space for up to 3 hours 10. Presence of continuous or excessive movements at rest or are unable remain supine while undergoing a scan for up to 3 hours 11. Presence of secondary form of tic disorder |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci. 2006 Mar;29(3):175-82. Epub 2006 Jan 23. Review. — View Citation
Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Neuroreport. 2000 Jul 14;11(10):2117-20. — View Citation
Baym CL, Corbett BA, Wright SB, Bunge SA. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain. 2008 Jan;131(Pt 1):165-79. Epub 2007 Dec 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1 & 2: Difference in BOLD signal in a ROI during neurofeedback after training compared to resting baseline. Phase 3: Change in YGTSS measured prior to neurofeedback training compared to the score measured at a follow-up visit. | |||
Secondary | Difference in BOLD signal in a ROI during neurofeedback compared to a resting baseline after subsequent scanning runs and during a transfer task, and in Phase 3 compared to controls. Also any changes of neurofeedback on various disease measures... |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01579149 -
A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent
|
Phase 1 | |
Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A | |
Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 |